France's Sanofi said its Dupixent drug jointly developed with Regeneron advanced toward a new indication for chronic hives in the European Union, while the U.S. Food and Drug Administration extended ...

Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis Paris, September 22, 2025. The US Food and Drug Administration (FDA) has extended by three ...

From an Emirati jewellery–inspired mobility device, to an AI reading tool, the projects showed an understanding of the daily ...

A Leicester woman suffering from pain in her eyes was given a life-changing diagnosis. Just weeks after the news, Millie-Mae ...

An analysis found that MS patients on a less frequent anti-CD20 therapy dosing schedule do not have more relapses or show ...

The latest revisions to the McDonald criteria seek to provide a unified framework for the most accurate diagnosis of MS ...

MS primarily affects young adults and is more common in women. The prevalence continues to rise globally, including in aging ...

Dr Jiwon Oh looks forward to hearing updates on major clinical trials and long-term studies of new and emerging MS treatments at ECTRIMS 2025.

AlterEgo's neural-interface device is non-invasive and is being tested in people with multiple sclerosis and amyotrophic ...

Drs Anne Cross and Scott Newsome discuss new horizons in MS treatment strategies, including the TREAT-MS trial and shared decision-making for optimal patient care.

NEW YORK, Sept. 18, 2025 /PRNewswire/ -- The McDonald Diagnostic Criteria for MS - a set of guidelines to help healthcare ...

Multiple sclerosis (MS) is a chronic autoimmune and neurodegenerative disease of the central nervous system (CNS), affecting ...